|
Disclaimer The
foregoing release contains forward-looking statements that can be identified
by terminology such as will strengthen, would have enhanced
opportunities, would be established, complementary assets, synergies,
estimated, expected, potential, accretive, dilutive, anticipate,
propose, enable, preserve, strategic, or similar expressions, or by
express or implied discussions regarding the potential impact on Novartis of
the proposed merger with Alcon, including express or implied discussions
regarding potential future sales or earnings of the Novartis Group or Alcon
and any potential synergies, strategic benefits or opportunities as a result
of the proposed merger. You should not place undue reliance on these
statements. Such forward-looking statements reflect the current views of
management regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee that
Novartis or Alcon will achieve any particular future financial results or
future growth rates or that Novartis or Alcon will be able to realize any
potential synergies, strategic benefits or opportunities as a result of the
proposed merger. Neither can there be any guarantee with respect to the
impact of the proposed transactions on the Groups credit rating. In
particular, management's expectations could be affected by, among other
things, uncertainties involved in the development of new generic
pharmaceutical products; unexpected patent litigation outcomes; unexpected
inabilities to obtain or maintain exclusivity periods for developed products;
unexpected regulatory actions or delays or government regulation generally;
uncertainty that the two businesses will be integrated successfully and that
key personnel will be retained; uncertainties that the cost savings and any
other synergies from the transaction may not be fully realized or may take
longer to realize than expected; disruption from the transaction making it
more difficult to maintain relationships with customers, employees or
suppliers; competition in general; government, industry, and general public
pricing and other political pressures; the impact that the foregoing factors
could have on the values attributed to the Group's assets and liabilities as recorded
in the Group's consolidated balance sheet; and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US Securities
and Exchange Commission. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected. Novartis is providing the information in this media
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this media release as a result of new
information, future events or otherwise.
2 | Investor presentation |
December 15, 2010 | Business Use Only
|